The endocannabinoid system modulates the release of excitatory and inhibitory
neurotransmitters in several brain areas implicated in motor control. Cannabinoid and …

The majority of Parkinson's disease patients undergoing levodopa therapy develop
disabling motor complications (dyskinesias) within 10 years of treatment. Stimulation of …

Dysregulation of the endocannabinoid system has been implicated in several
neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of …

The endocannabinoid system plays a regulatory role in a number of physiological processes
and has been found altered in different pathological conditions, including movement …

There is substantial evidence supporting a role for the endocannabinoid system as a
modulator of the dopaminergic activity in the basal ganglia, a forebrain system that …

Endocannabinoids and cannabinoid CB1 receptors play a role in the control of movement
by modulating GABA, glutamate, and other neurotransmitters throughout the basal ganglia …

Levodopa is the most commonly prescribed drug for Parkinson's disease (PD). Although
levodopa improves PD symptoms in the initial stages of the disease, its long-term use is …

In recent years, the endocannabinoid system has emerged as a potential therapeutic target
for the treatment of Parkinson's disease (PD). This is based on a number of convergent lines …

Clinical and animal model data support the view that the endocannabinoid system
participates in control of motor activity and in basal ganglia-related movement disorders …

The long-term use of levodopa as a pharmacotherapy for Parkinson's disease is limited by
the development of levodopa-induced dyskinesias. However, recent studies have suggested …